UNIVERSAL Business Summary

Universal Vision Biotechnology Co., Ltd. (3218.TWO) operates as a premier integrated vision care provider in Taiwan and Mainland China, utilizing a multi-pronged revenue model centered on ophthalmic medical services and optical retail. The company generates revenue through two primary segments: its Ophthalmology Business, which provides laser vision correction (LASIK/SMILE), cataract surgeries, and technical consultancy to franchised clinics, and its Optometry Business, which manages a retail network for prescription eyeglasses, contact lenses, and orthokeratology supplies. Additionally, the firm earns through the leasing of advanced medical equipment and the provision of medical cosmetology services. Within the regional healthcare landscape, Universal Vision competes directly with Bionet Corp (1784.TW), Excelsior Medical Co. (4104.TW), and CHC Healthcare Group (4164.TW), distinguishing itself through a "one-stop" vertical integration strategy that links clinical treatment with retail dispensing. The company was founded in 1994 by the husband-and-wife team of Dr. Pi-Jung Lin and Dr. Shu-Fang Ou, both of whom are distinguished ophthalmologists. As of March 2026, the leadership team is led by Chairperson Dr. Shu-Fang Ou, who holds a PhD in Biomedical Engineering and an MD, and CEO Kenneth Lu, who oversees global operations and ESG integration. Dr. Pi-Jung Lin continues to serve as the Chief Technology Officer (CTO), leveraging his clinical expertise to spearhead the adoption of cutting-edge surgical technologies. The board is supported by independent directors such as Min-Zhi Xiao and Vincent Liu, while the shareholder base includes significant institutional backing from global funds such as Vanguard and Dimensional Fund Advisors, alongside the founders' substantial equity stakes.